Biological and immunomodulator use in Crohn's disease in a medicaid population

Inflammatory Bowel Diseases

Volumn 22, Issue 5, 2016, Pages 1056-1064

  Flasar, Mark H ^a   Chao, Jingdong ^b   Ozbay, A Burak ^b   Skup, Martha ^b   Lu, Mei ^c   Cross, Raymond ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b ABBVIE INC   (United States)

^c ANALYSIS GROUP   (United States)

Author keywords

biologic; Crohn's disease; disparities; immunomodulator

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BIOLOGICAL PRODUCT; BUDESONIDE; CERTOLIZUMAB PEGOL; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; NATALIZUMAB; PREDNISONE; BIOLOGICAL FACTOR; IMMUNOLOGIC FACTOR;

ADULT; AFRICAN AMERICAN; ARTICLE; BIOLOGICAL THERAPY; COHORT ANALYSIS; CROHN DISEASE; FEMALE; HEALTH CARE UTILIZATION; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; PRIORITY JOURNAL; RETROSPECTIVE STUDY; CAUCASIAN; COMORBIDITY; FOLLOW UP; PROGNOSIS; UNITED STATES;

ADULT; AFRICAN AMERICANS; BIOLOGICAL FACTORS; COMORBIDITY; CROHN DISEASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HISPANIC AMERICANS; HUMANS; IMMUNOLOGIC FACTORS; MALE; MEDICAID; PROGNOSIS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84964885444     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000730     Document Type: Article

References (34)

1. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006; 130: 940-987
2. Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008; 135: 1493-1499
3. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. 2005; 128: 862-869
4. Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol. 2002; 35: 151-156
5. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 1541-1549
6. Odes S. How expensive is inflammatory bowel disease'. A critical analysis. World J Gastroenterol. 2008; 14: 6641-6647
7. Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther. 2009; 30: 265-274
8. Lindsay J, Punekar YS, Morris J, et al. Health-economic analysis: costeffectiveness of scheduled maintenance treatment with infliximab for Crohn's disease-modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther. 2008; 28: 76-87
9. Jackson JF, Kornbluth A. Do black and Hispanic Americans with inflammatory bowel disease (IBD) receive inferior care compared with white Americans'. Uneasy questions and speculations. Am J Gastroenterol. 2007; 102: 1343-1349
10. Ullman T. Disparities in inflammatory bowel disease care: time to correct a problem. Gastroenterology. 2008; 134: 1617-1618; discussion 1618-1619
11. Nguyen GC, Bayless TM, Powe NR, et al. Race and health insurance are predictors of hospitalized Crohn's disease patients undergoing bowel resection. Inflamm Bowel Dis. 2007; 13: 1408-1416
12. Nguyen GC, Laveist TA, Gearhart S, et al. Racial and geographic variations in colectomy rates among hospitalized ulcerative colitis patients. Clin Gastroenterol Hepatol. 2006; 4: 1507-1513
13. Nguyen GC, Munsell M, Brant SR, et al. Racial and geographic disparities in the use of parenteral nutrition among inflammatory bowel disease inpatients diagnosed with malnutrition in the United States. JPEN J Parenter Enteral Nutr. 2009; 33: 563-568
14. Dotson JL, Kappelman MD, Chisolm DJ, et al. Racial disparities in readmission, complications, and procedures in children with Crohn's disease. Inflamm Bowel Dis. 2015; 21: 801-808
15. Flasar MH, Johnson T, Roghmann MC, et al. Disparities in the use of immunomodulators and biologics for the treatment of inflammatory bowel disease: a retrospective cohort study. Inflamm Bowel Dis. 2008; 14: 13-19
16. Cross RK, Jung C, Wasan G, et al. Racial differences in disease phenotypes in patients with Crohn's disease. Inflamm Bowel Dis. 2006; 12: 192-198
17. Nguyen GC, LaVeist TA, Harris ML, et al. Racial disparities in utilization of specialist care and medications in inflammatory bowel disease. Am J Gastroenterol. 2010; 105: 2202-2208
18. Center for Medicare & Medicaid Services. National Health Expenditure Projections 2009-2019 [Centers for Medicare & Medicaid Services Website]. 2010. Available at: https://www.cms.gov/NationalHealthExpendData/downloads/NHEProjections2009to2019.pdf. Accessed January 19, 2015
19. Ray WA, Griffin MR. Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol. 1989; 129: 837-849
20. Iglehart JK. The American health care system-Medicaid. N Engl J Med. 1999; 340: 403-408
21. Deyo RA, Cherkin DC, Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45: 613-619
22. SAS [computer Program]. Version 9.2. SAS Institute Inc. Cary, NC: SAS Institute Inc.; 2011
23. Ghazi LJ, Lydecker AD, Patil SA, et al. Racial differences in disease activity and quality of life in patients with Crohn's disease. Dig Dis Sci. 2014; 59: 2508-2513
24. Reddy SI, Friedman S, Telford JJ, et al. Are patients with inflammatory bowel disease receiving optimal care'. Am J Gastroenterol. 2005; 100: 1357-1361
25. Nguyen GC, Torres EA, Regueiro M, et al. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol. 2006; 101: 1012-1023
26. Straus WL, Eisen GM, Sandler RS, et al. Crohn's disease: does race matter'. The Mid-Atlantic Crohn's disease study group. Am J Gastroenterol. 2000; 95: 479-483
27. Basu D, Lopez I, Kulkarni A, et al. Impact of race and ethnicity on inflammatory bowel disease. Am J Gastroenterol. 2005; 100: 2254-2261
28. Finlay DG, Basu D, Sellin JH. Effect of race and ethnicity on perceptions of inflammatory bowel disease. Inflamm Bowel Dis. 2006; 12: 503-507
29. Pressman AR, Hutfless S, Velayos F, et al. Patterns of infliximab use among Crohn's disease patients in a community setting. Inflamm Bowel Dis. 2008; 14: 1265-1272
30. Hou JK, El-Serag H, Thirumurthi S. Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: a systematic review. Am J Gastroenterol. 2009; 104: 2100-2109
31. Sewell JL, Inadomi JM, Yee HF Jr. Race and inflammatory bowel disease in an urban healthcare system. Dig Dis Sci. 2010; 55: 3479-3487
32. De Navas-Walt C, Proctor BD, Smith JC. Income, Poverty, and Health Insurance Coverage in the United States: 2009 [United States Census Bureau Website]. 2010. Available at: http://www.census.gov/prod/2010pubs/p60-238.pdf. Accessed January 19, 2015
33. D'Haens G, Baert F, Van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008; 371: 660-667
34. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362: 1383-1395